Galidesivir (BCX4430) is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy.
Galidesivir (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF).
Animal Model: |
Female Syrian golden hamsters (hamsters infected with YF virus) |
Dosage: |
4 mg/kg of body weight |
Administration: |
I.p.; twice daily for 7 days |
Result: |
Significantly improved the survival of hamsters infected with YFV.
|